Company / PP&E (Net)
SUTRO BIOPHARMA, INC. PP&E (Net) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$10.6M
FY2025
5-year range
$10.6M / $24.6M
FY2021-FY2025
Trend
-41.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has declined for 3 consecutive years, from $25M in FY2022 to $11M in FY2025.
Based on SEC 10-K filings.
$11M in FY2025 with a 5-year CAGR of -3.8%.
Declined from $22M to $11M over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -24.4%
- 5-Year CAGR
- -3.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- SUTRO BIOPHARMA, INC.'s pp&e (net) has declined for 3 consecutive years.
- 5-year CAGR of -3.8%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 41.5% year-over-year.
- Peak pp&e (net) was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -3.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.6M | -41.5% |
| FY2024 | $18.2M | -17.1% |
| FY2023 | $21.9M | -10.9% |
| FY2022 | $24.6M | +9.2% |
| FY2021 | $22.6M | +74.3% |
| FY2020 | $12.9M | +34.3% |
| FY2019 | $9.6M | -11.9% |
| FY2018 | $10.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026